Get started
Bristol-Myers Squibb Company Shs Cert Deposito Arg Repr 0.333333 ShBristol-Myers Squibb Company Shs Cert Deposito Arg Repr 0.333333 ShBristol-Myers Squibb Company Shs Cert Deposito Arg Repr 0.333333 Sh

Bristol-Myers Squibb Company Shs Cert Deposito Arg Repr 0.333333 Sh

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

BMY chart


Full chart

Key facts today


Zydus Lifesciences has secured an exclusive licensing and supply agreement with Synthon BV for Ozanimod Capsules, a generic version of Bristol Myers Squibb's ZEPOSIA, aimed at the U.S. market.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪131.72 T‬ ARS
Dividend yield (indicated)
3.33%
Price to earnings Ratio (TTM)
25
Basic EPS (TTM)
875 ARS
Net income (FY)
‪−8.19 T‬ ARS
Revenue (FY)
‪44.23 T‬ ARS
Shares float
—
Beta (1Y)
0.02

About Bristol-Myers Squibb Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Christopher S. Boerner
Website
bms.com
Headquarters
Princeton
Founded
1933
ISIN
ARDEUT112877
FIGI
BBG000L7BMZ1
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Check out other big names from the same industry as BMY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BMY news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BMY highest yielding bonds


BMY5009254
Bristol-Myers Squibb Company 4.25% 26-OCT-2049
Yield to maturity
—
Maturity date
Oct 26, 2049
BMY.GL
Bristol-Myers Squibb Company 5.875% 15-NOV-2036
Yield to maturity
—
Maturity date
Nov 15, 2036
BMY3883364
Bristol-Myers Squibb Company 3.25% 01-AUG-2042
Yield to maturity
—
Maturity date
Aug 1, 2042
BMY5007343
Bristol-Myers Squibb Company 4.125% 15-JUN-2039
Yield to maturity
—
Maturity date
Jun 15, 2039
BMY5077468
Bristol-Myers Squibb Company 1.45% 13-NOV-2030
Yield to maturity
—
Maturity date
Nov 13, 2030
BMY5007342
Bristol-Myers Squibb Company 3.4% 26-JUL-2029
Yield to maturity
—
Maturity date
Jul 26, 2029
C
BMY4560450
Celgene Corporation 3.45% 15-NOV-2027
Yield to maturity
—
Maturity date
Nov 15, 2027
BMY5009253
Bristol-Myers Squibb Company 4.625% 15-MAY-2044
Yield to maturity
—
Maturity date
May 15, 2044
BMY4931963
Bristol-Myers Squibb Company 4.55% 20-FEB-2048
Yield to maturity
—
Maturity date
Feb 20, 2048
BMY5009250
Bristol-Myers Squibb Company 4.55% 20-FEB-2048
Yield to maturity
—
Maturity date
Feb 20, 2048
BMY5754772
Bristol-Myers Squibb Company FRN 20-FEB-2026
Yield to maturity
—
Maturity date
Feb 20, 2026

See all BMY bonds 

Sparks


Curated watchlists where BMY is featured.

See all sparks